Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Rande Is . . . HOME -- Ignore unavailable to you. Want to Upgrade?

To: Rande Is who wrote (28497)	6/26/2000 10:27:00 AM
From: johnsto1	Respond to of 57584

ORCH...new leader in next PHASE OF GENEOMICS...SNP'S June 26, 2000 -------------------------------------------------------------------------------- New Race Heats Up to Turn Gene Information Into Drug Discoveries By SCOTT HENSLEY Staff Reporter of THE WALL STREET JOURNAL Monday's expected announcement that Celera Genomics Group and a consortium of public researchers have finished sequencing much of the human genome is what some scientists are calling "the end of the beginning" in genomic research. Painstaking putting into proper order the roughly three billion chemical letters that make up human DNA will have little practical value until scientists can use that information to find and understand the more than 60,000 human genes. The real race, now heating up at biotechnology and drug companies around the world, is to be the first to find and patent the key disease-related genes. "Genomics to me is not an end. It's a means to get better medicines out," says Dr. Goran Ando, president of research and development at Pharmacia Corp. in Peapack, N.J. The torrent of genetic information brings a bounty of new targets for drug development, he says, yet the sheer volume of data presents a daunting challenge. That's where "very sophisticated bioinformatics" comes in, Dr. Ando says. A host of companies specializing in bioinformatics -- that is, the analysis and management of genetic data -- are jostling to take the raw genetic information and turn it into practical knowledge for drug discovery and development. Some are specialists serving drug companies; others are using the information to develop drugs themselves. -------------------------------------------------------------------------------- Genetic Translators Companies helping turn DNA data into drugs: Company Approach Customers Celera Genomics Group (Rockville, Md.) Sequencing champion and developer of genetic libraries plus software tools to analyze them Amgen, Novartis, Pfizer CuraGen (New Haven, Conn.) Pinpoints genetic variations, function and level of activity to aid drug development Biogen, Hoffman-LaRoche, GlaxoWellcom DoubleTwist (Oakland, Calif.) An Internet portal for genetics reasearchers with an assortment of databases and information management tools Chiron, Corp., Genaissance Pharmaceuticals, Tularik Exelixis (South San Francisco, Calif.) Links human genes and disease by comparing genetic information from the fruit fly, round worm, yeast and man Bayer AG, Bristol-Myers Squibb and Pharmacia GeneLogic (Gaithersburg, Md.) Combines software tools and genomic databases to determine the activity of genes in normal, diseased and treated conditions Merck & Co., Pfizer, Schering-Plough Orchid BioSciences (Princeton, N.J.) Combines computerized databases and automated chemical analysis to analyze genetic diversity SmithKline Beecham, Millennium Pharmaceuticals, SNP Consortium -------------------------------------------------------------------------------- Write to Scott Hensley at scott.hensley@wsj.com

To: Rande Is who wrote (28497)	6/26/2000 10:29:00 AM
From: carepedeum2000	Read Replies (1) \| Respond to of 57584

yhoo alert- if you believe like i do that the market will rally into fed meeting, then yahoo has to be attractive here, fell hard due to amzn crunch, but still on merril's top 26 list, earnings due on july 11th, and it is the leading internet company, some people defending amazon here, yahoo should have hard bounce shortly, negative is chart doesnt look good, but im buying the fundamentals here, unless they continue kicing the internets, this one will bounce first, under 120 area is fairly safe entry imo